A detailed history of Acadian Asset Management LLC transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Acadian Asset Management LLC holds 3,841 shares of SRRK stock, worth $169,849. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,841
Holding current value
$169,849
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$7.63 - $9.71 $29,306 - $37,296
3,841 New
3,841 $30,000
Q1 2023

May 11, 2023

SELL
$7.36 - $12.72 $2.04 Million - $3.53 Million
-277,309 Reduced 79.84%
70,010 $559,000
Q4 2022

Feb 14, 2023

SELL
$7.02 - $9.76 $869,735 - $1.21 Million
-123,894 Reduced 26.29%
347,319 $3.14 Million
Q3 2022

Nov 14, 2022

SELL
$5.33 - $11.3 $979,765 - $2.08 Million
-183,821 Reduced 28.06%
471,213 $3.26 Million
Q2 2022

Aug 09, 2022

BUY
$4.66 - $13.96 $3.05 Million - $9.14 Million
655,034 New
655,034 $3.6 Million
Q4 2020

Feb 11, 2021

SELL
$13.72 - $51.57 $344,083 - $1.29 Million
-25,079 Closed
0 $0
Q3 2020

Nov 09, 2020

SELL
$10.54 - $18.47 $327,983 - $574,749
-31,118 Reduced 55.37%
25,079 $444,000
Q2 2020

Aug 12, 2020

SELL
$10.37 - $20.64 $85,811 - $170,796
-8,275 Reduced 12.84%
56,197 $1.02 Million
Q1 2020

May 11, 2020

BUY
$9.63 - $17.14 $37,508 - $66,760
3,895 Added 6.43%
64,472 $781,000
Q4 2019

Feb 06, 2020

BUY
$7.2 - $13.2 $26,568 - $48,708
3,690 Added 6.49%
60,577 $799,000
Q3 2019

Nov 07, 2019

BUY
$8.95 - $15.72 $121,782 - $213,902
13,607 Added 31.44%
56,887 $509,000
Q2 2019

Aug 08, 2019

BUY
$14.61 - $22.45 $403,221 - $619,597
27,599 Added 176.0%
43,280 $687,000
Q1 2019

May 09, 2019

BUY
$14.24 - $22.28 $223,297 - $349,372
15,681 New
15,681 $295,000

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $2.28B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.